Skip to main content

personalised Diabetes Management using lOw-cost Needle-free multiple-biomarkers monitoring Device

Cel

"""Diabetes is the #1 health challenge of the 21st century. Continuous Glucose Monitoring or CGM ($1.25B market in 2016, growing 29%/yr) is today’s cornerstone of “diabetes self-management” and the most effective solution to reduce the economic and societal burden of diabetes. But the shortcomings of current CGMs hinder their wider adoption: high cost, unsatisfactory predictability of severe events, and poor user comfort. The DiaMOND project will remove these barriers by bringing needle-free, low-cost Continuous Diabetes Monitoring to market. DiaMOND is specifically geared at extending Indigo’s current CGM with reliable severe clinical event prediction and a great user experience; demonstrating the reliability in a first-in-man trial; creating market acceptance by involving Key Opinion Leaders; and obtaining reimbursement. Indigo will be ready for a large pivotal clinical study and CE marking after completing the DiaMOND project. DiaMOND will accelerate Indigo’s CDM market access by 2-3 years."""

Zaproszenie do składania wniosków

H2020-EIC-SMEInst-2018-2020

Zobacz inne projekty w ramach tego zaproszenia

Szczegółowe działanie

H2020-SMEInst-2018-2020-2

Koordynator

INDIGO DIABETES
Wkład UE netto
€ 2 493 273,13
Adres
Bollebergen 2b/30
9052 Gent
Belgia

Zobacz na mapie

Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Środki z innych źródeł
€ 2 026 135,62